Idiopathic Pulmonary fibrosis (IPF) is a subset of interstitial lung diseases, where in the normal ageing of lung is augmented. It is characterised by fibrosis of the lung architecture which ...

Idiopathic pulmonary fibrosis (IPF) is a debilitating idiopathic lung disease that leads to early death. There are no effective medical therapies for IPF. Recent discoveries have identified a ...

In an official statement released by his family, it was confirmed that Hussain died due to Idiopathic Pulmonary Fibrosis (IPF), a rare lung disease. "His prolific work as a teacher, mentor and ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

More than 4,000 doses of PRM-151 have been administered to more than 250 patients over 6 years, and Promedior has just completed phase 2 trials in patients with idiopathic pulmonary fibrosis (IPF ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...